These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24023335)

  • 1. Comparisons of late vaginal mucosal reactions between interstitial and conventional intracavitary brachytherapy in patients with gynecological cancer: speculation on the relation between pallor reaction and stenosis.
    Yoshida K; Yamazaki H; Nakamura S; Masui K; Kotsuma T; Baek SJ; Akiyama H; Tanaka E; Yoshioka Y
    Anticancer Res; 2013 Sep; 33(9):3963-8. PubMed ID: 24023335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-irradiation using interstitial brachytherapy increases vaginal mucosal reaction compared to initial brachytherapy in patients with gynecological cancer.
    Yoshida K; Yamazaki H; Nakamura S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Yoshioka Y
    Anticancer Res; 2013 Dec; 33(12):5687-92. PubMed ID: 24324118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal analysis of late vaginal mucosal reactions after high-dose-rate brachytherapy in patients with gynecological cancer.
    Yoshida K; Yamazaki H; Nakamura S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Narumi Y; Yoshioka Y
    Anticancer Res; 2014 Aug; 34(8):4433-8. PubMed ID: 25075082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of vaginal pallor reaction in predicting late vaginal stenosis after high-dose-rate brachytherapy in treatment-naive patients with cervical cancer.
    Yoshida K; Yamazaki H; Nakamura S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Yoshikawa N; Uesugi Y; Shimbo T; Narumi Y; Yoshioka Y
    J Gynecol Oncol; 2015 Jul; 26(3):179-84. PubMed ID: 25925294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study.
    Kirchheiner K; Nout RA; Tanderup K; Lindegaard JC; Westerveld H; Haie-Meder C; Petrič P; Mahantshetty U; Dörr W; Pötter R
    Int J Radiat Oncol Biol Phys; 2014 May; 89(1):88-95. PubMed ID: 24725693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of prognostic factors for vaginal mucosal toxicity associated with intravaginal high-dose rate brachytherapy in patients with endometrial cancer.
    Bahng AY; Dagan A; Bruner DW; Lin LL
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):667-73. PubMed ID: 21300451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose-rate intracavitary brachytherapy for cervical carcinomas with lower vaginal infiltration.
    Kazumoto T; Kato S; Tabushi K; Kutsutani-Nakamura Y; Mizuno H; Takahashi M; Shiromizu K; Saito Y
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1157-66. PubMed ID: 17459604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: clinical outcomes and dose--volume histogram analysis.
    Thibault I; Lavallée MC; Aubin S; Laflamme N; Vigneault E
    Brachytherapy; 2012; 11(3):181-91. PubMed ID: 21862418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes and Dosimetric Evaluationof Interstitial Brachytherapyin Gynecological Malignancies.
    V VN; Dharmarajan A; Jones J; Yahiya EKN; Muttath G; Sneha N
    Gulf J Oncolog; 2024 May; 1(45):69-74. PubMed ID: 38774935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective cohort study to compare treatment results between 2 fractionation schedules of high-dose-rate intracavitary brachytherapy (HDR-ICBT) in patients with cervical cancer.
    Huang EY; Sun LM; Lin H; Lan JH; Chanchien CC; Huang YJ; Wang CY; Wang CJ
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):123-8. PubMed ID: 22672751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Californium-252 brachytherapy combined with external-beam radiotherapy for cervical cancer: long-term treatment results.
    Lei X; Qian CY; Qing Y; Zhao KW; Yang ZZ; Dai N; Zhong ZY; Tang C; Li Z; Gu XQ; Zhou Q; Feng Y; Xiong YL; Shan JL; Wang D
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1264-70. PubMed ID: 21435797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer.
    Yoshida K; Yamazaki H; Takenaka T; Kotsuma T; Yoshida M; Furuya S; Tanaka E; Uegaki T; Kuriyama K; Matsumoto H; Yamada S; Ban C
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):765-72. PubMed ID: 19836165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage Re-irradiation With Single-modality Interstitial Brachytherapy for the Treatment of Recurrent Gynaecological Tumours in the Pelvis: A Multi-institutional Study.
    Raziee H; D'Souza D; Velker V; Barnes E; Taggar A; Mendez L; Leung E
    Clin Oncol (R Coll Radiol); 2020 Jan; 32(1):43-51. PubMed ID: 31402286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late effects of post-high-dose-rate brachytherapy for oropharyngeal carcinoma: are they severer than post-low-dose-rate?
    Nose T; Peiffert D; Lapeyre M; Hoffstetter S; Koizumi M; Nishiyama K
    Strahlenther Onkol; 2004 Dec; 180(12):776-82. PubMed ID: 15592697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of salvage high-dose-rate brachytherapy with or without external beam radiotherapy for isolated vaginal recurrence of endometrial cancer.
    Sekii S; Murakami N; Kato T; Harada K; Kitaguchi M; Takahashi K; Inaba K; Igaki H; Ito Y; Sasaki R; Itami J
    J Contemp Brachytherapy; 2017 Jun; 9(3):209-215. PubMed ID: 28725243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of interstitial brachytherapy using template in locally advanced gynecological malignancies.
    Agrawal PP; Singhal SS; Neema JP; Suryanarayan UK; Vyas RK; Rathi AK; Bahadur AK
    Gynecol Oncol; 2005 Oct; 99(1):169-75. PubMed ID: 16081150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three or four fractions of 4-5 Gy per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma.
    Rovirosa A; Ascaso C; Sánchez-Reyes A; Herreros A; Abellana R; Pahisa J; Lejarcegui JA; Biete A
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):418-23. PubMed ID: 20800388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective analysis of catheter complications for gynecological cancers treated with interstitial brachytherapy in the 3D era.
    Mendez LC; Lang P; Patel C; D'Souza D; Gladwish A; D'Alimonte L; Taggar A; Barnes E; Barbera L; Leung E
    Brachytherapy; 2019; 18(1):44-49. PubMed ID: 30316724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomography planned interstitial brachytherapy for recurrent gynecologic cancer.
    Amsbaugh MJ; Bhatt N; Hunter T; Gaskins J; Parker L; Metzinger D; Amsbaugh A; Sowards K; El-Ghamry M
    Brachytherapy; 2015; 14(5):600-5. PubMed ID: 26087868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.